HK Recently Listed Stocks Watch | MICOT PHARMA-B (02335.HK): 1H R&D Expenses Up 215.9% YoY, 24.681 Million Cornerstone Lock-up Shares to Be Unlocked on December 24
- MICOT PHARMA-B (02335.HK) listed on the Main Board of The Stock Exchange of Hong Kong Limited on June 24, 2026 at an offer price of HKD 18.20, with a global offering of 58.0544 million H shares.
- the company disclosed its first interim results after listing in August 2026, with R&D expenses of approximately RMB 128 million for the first half of 2026, up 215.9% year on year.
- Founded in 2007 and headquartered in Xi'an, MICOT PHARMA-B (02335.HK) is a biotechnology company focusing on the discovery, development and commercialization of bispecific/multi-specific peptide drugs.
NewTimeSpace News: On October 13, 2026, MICOT PHARMA-B (02335.HK) traded weakly, with the company quoting HKD 19.94 as of 14:38, down 8.95%.
On the news front, according to previous disclosures, 3 cornerstone investors collectively hold 24.681 million H shares, with lock-up periods all ending on December 23, 2026 and official unlocking from December 24, 2026, corresponding to a market value of approximately HKD 449 million based on the offer price. The cornerstone lineup involves Qiyuan Hong Kong, EVEREST MED and Shunming Capital.
According to public information, MICOT PHARMA-B (02335.HK) listed on the Main Board of The Stock Exchange of Hong Kong Limited on June 24, 2026 at an offer price of HKD 18.20, with a global offering of 58.0544 million H shares; gross proceeds were approximately HKD 1.057 billion and net proceeds HKD 989 million; the Hong Kong public offering was 1,181.46 times subscribed and the international offering 2.52 times subscribed.
In terms of performance, the company disclosed its first interim results after listing in August 2026, with R&D expenses of approximately RMB 128 million for the first half of 2026, up 215.9% year on year; the adjusted net loss for the period was approximately RMB 112 million, widened by 128.5% year on year.
GUOSEN SECURITIES noted that MICOT PHARMA is a leading enterprise in China's peptide drug field; represented by its core product MT1013 (a dual-target receptor agonist peptide targeting CaSR and OGP receptors), the company has built an innovative drug pipeline covering metabolic diseases and cardiovascular and cerebrovascular diseases, with MT1013 in a Phase III clinical trial in China and expected to complete the study and submit a pre-NDA by the end of 2026.
Founded in 2007 and headquartered in Xi'an, MICOT PHARMA-B (02335.HK) is a biotechnology company focusing on the discovery, development and commercialization of bispecific/multi-specific peptide drugs, with a key focus on metabolic diseases and cardiovascular and cerebrovascular diseases.
- HK Recently Listed Stocks Watch | DAJIN (01081.HK): 1H Revenue Up 14.48% YoY, 43.1609 Million Cornerstone Lock-up Shares to Be Unlocked on December 5
- HK Recently Listed Stocks Watch | HUAQIN (03296.HK): 29.2501 Million Cornerstone Lock-up Shares to Be Unlocked on October 23
- HK Recently Listed Stocks Watch | FS.COM (03355.HK): 16.9229 Million Cornerstone Lock-up Shares to Be Unlocked on September 23
- MICOT PHARMA-B (02335.HK): H shares included in eligible list under Stock Connect
- Micot (02335.HK): Phase‑II Clinical Trial of MT200605 for Acute Ischemic Stroke Completed, AKI Incidence Reduced by Over 80% in High‑dose Cohort
